Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2024 | $195.00 → $204.00 | Buy → Neutral | Citigroup |
| 11/20/2023 | $160.00 | Buy | Goldman |
| 10/24/2023 | $100.00 | Overweight | Cantor Fitzgerald |
| 10/12/2023 | $160.00 | Buy | Citigroup |
| 9/7/2023 | $154.00 | Buy | Berenberg |
| 4/18/2023 | $102.00 | Buy | Stifel |
| 2/28/2023 | $79.00 → $124.00 | Neutral → Buy | Goldman |
| 8/25/2022 | $74.00 | Buy → Neutral | Goldman |
For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a
10-Q - Krystal Biotech, Inc. (0001711279) (Filer)
8-K - Krystal Biotech, Inc. (0001711279) (Filer)
144 - Krystal Biotech, Inc. (0001711279) (Subject)
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer -- Industry veterans and leading academic experts joined Attovia's Clinical and Scientific Advisory Boards: Jonathan Silverberg, M.D., Ph.D., M.P.H., Lawrence Eichenfield, M.D., Brian Kim, M.D., MTR, Sonja Ständer, M.D., Dedee Murrell, M.D., D.Sc., Richard Heyman, Ph.D., Luisa Salter-Cid, Ph.D., and David King, Ph.D. FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug develo
Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Mr. Naftzger succeeds Dr. Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement l
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 1:30 pm ET on Tuesday, November 12, 2024 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ:KRYS) is a c
Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health authority approved pre-marketing early reimbursed access for B-VEC in France under the Accès Précoce (AP1) program; AP1 program for DEB patients access expected to start in 4Q 2024 Advancing Jeune Aesthetics' KB301 to Phase 2 after positive results in Phase 1 Clinical updates on AATD and oncology program before end of year Strong balance sheet, ending the quarter with $694.2 million in cash and investments PITTSBURGH, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc.
PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, November 4, 2024, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/51458. For those unable to listen to the live webcast, a replay will be available for 30 days on the Investors section of the
Citigroup downgraded Krystal Biotech from Buy to Neutral and set a new price target of $204.00 from $195.00 previously
Goldman initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $160.00
Cantor Fitzgerald initiated coverage of Krystal Biotech with a rating of Overweight and set a new price target of $100.00
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 21.75% on an annualized basis producing an average annual return of 34.64%. Currently, Krystal Biotech has a market capitalization of $5.82 billion. Buying $100 In KRYS: If an investor had bought $100 of KRYS stock 5 years ago, it would be worth $426.51 today based on a price of $203.66 for KRYS at the time of writing. Krystal Biotech's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated cont
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 19.45% on an annualized basis producing an average annual return of 32.47%. Currently, Krystal Biotech has a market capitalization of $5.47 billion. Buying $1000 In KRYS: If an investor had bought $1000 of KRYS stock 5 years ago, it would be worth $4,238.23 today based on a price of $191.69 for KRYS at the time of writing. Krystal Biotech's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated
Krystal Biotech's (NYSE:KRYS) short percent of float has risen 7.87% since its last report. The company recently reported that it has 2.90 million shares sold short, which is 13.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.23 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short intere
SC 13G - Krystal Biotech, Inc. (0001711279) (Subject)
SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health authority approved pre-marketing early reimbursed access for B-VEC in France under the Accès Précoce (AP1) program; AP1 program for DEB patients access expected to start in 4Q 2024 Advancing Jeune Aesthetics' KB301 to Phase 2 after positive results in Phase 1 Clinical updates on AATD and oncology program before end of year Strong balance sheet, ending the quarter with $694.2 million in cash and investments PITTSBURGH, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc.
PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, November 4, 2024, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/51458. For those unable to listen to the live webcast, a replay will be available for 30 days on the Investors section of the
Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin, announced today positive interim safety and efficacy results from both Cohorts 3 and 4 of PEARL-1, a Phase 1 study evaluating KB301, an investigational aesthetic treatment designed to deliver the COL3A1 transgene and increase type III